Key Inputs in the Model: Chinese ASCVD Cost-Effectiveness Analysis

China-focused economic model inputs evaluating the cost-effectiveness of inclisiran for atherosclerotic cardiovascular disease (ASCVD). The dataset, shared by Mochou Liu on figshare, contains parameters for a Markov cohort model, including clinical inputs, costs, and utilities derived from published literature and clinical trials. It was last updated in May 2026.

Use Cases

• Evaluating cost-effectiveness of novel siRNA therapies based on incremental cost-effectiveness ratio (ICER) calculations.
• Conducting sensitivity analyses on model drivers based on parameters like mortality reduction effect and discount rate.
• Assessing the economic value of pharmaceutical interventions under China's willingness-to-pay threshold of CNY 191,498 per QALY.

Strengths

• Model inputs are derived from published literature and clinical trials, as stated in the description.
• The dataset includes specific economic parameters, such as a discount rate of 4.5% and a WTP threshold of CNY 191,498 per QALY.
• The analysis includes both one-way and probabilistic sensitivity analyses to assess model uncertainty.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is small (9.5 KB), indicating a limited scope focused on model parameters rather than patient-level data.

Provenance

Source

Mochou Liu via figshare.

Collection Method

Derived from published literature and clinical trials for a health economic model.

Freshness

Last updated 2026-05-28 17:30:44; freshness should be verified.

Geography

China